Elixir Pharmaceuticals Announces Issuance of SIRT Patent Covering Development of New Therapies Based on Breakthrough Science
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc., announced today issuance of U.S. Patent No. 7,351,542, which covers the discovery of new and existing chemical entities that modulate the activity of a human sirtuin, SIRT 2. Elixir’s rights to this patent were made possible through an exclusive license.